Sequencing Considerations in mCRPC

Dana-Farber Cancer Institute
A

Lecture Summary - CARD Trial: Safety and Efficacy of Cabazitaxel in mCRPC & Age Subgroup Analysis

By Dana-Farber Cancer Institute FEATURING Atish Choudhury
By Dana-Farber Cancer Institute FEATURING Atish Choudhury
19 views
July 28, 2022
Comments 0
Login to view comments. Click here to Login
09:06

CARD Trial: Safety and Efficacy of Cabazitaxel in mCRPC & Age Subgro…

Dana-Farber Cancer Institute

A. Choudhury

169 views
08:33

Challenging Genitourinary Tumors: What’s New in Prostate Cancer

Penn Medicine Abramson Cancer Center

V. Narayan

77 views
22:50

Genetics/Genomics in Prostate Cancer

Stanford Medicine

M. Cooperberg

97 views
23:27

Stanford Medicine Historical Landscape of Testing: Blood-Based Diagn…

Stanford Medicine

J. Leppert

38 views
38:10

ASCO 2022 Updates on Molecular Based Imaging for Prostate Cancer: Re…

Nebraska Oncology Society

T. Hope

242 views
21:43

ASCO 2022 on the Latest Developments in mHSPC and mCRPC

ecancer

H. Payne, K. Chi, K. Miller, L. Krabbe

240 views
44:50

New Therapeutic Discoveries and Mechanisms for CRPC

Masonic Cancer Center, University of Minnesota

K. Kelly

94 views
14:33

Prostate Cancer Imaging Updates: What, Why, and When

Martin Allen-Auerbach

899 views
06:00

Cabazitaxel Activity in Men With mCRPC With & Without DNA Damage Rep…

Elena Castro

245 views
10:02

The Role of Biomarkers in mCRPC

Eleni Efstathiou

177 views
13:49

Finding the Optimal Sequence for mCRPC

Benjamin L. Maughan

350 views
07:31

Second Line Therapy Options in mCRPC

Karam Al-Issa

160 views
06:12

Patient Preference Between Cabazitaxel and Docetaxel for 1L Chemothe…

Giulia Baciarello

170 views